The new generation of cancer treatments

Cantargia's CAN04 antibody treatment fights cancer by activating the immune system, and by blocking signals that lead to tumour growth.

Read more

Cantargia Team – passion for innovation and results

Read more

Development of new antibody-based cancer treatments

Read more

Latest press releases

(R) Cantargia publishes prospectus in connection with the list change to Nasdaq Stockholm’s main market

(R) Cantargia obtains patent approval for the antibody CAN04 (nidanilimab) in Japan

(R) Cantargia has been approved for listing on the main market of Nasdaq Stockholm

* (R) = Regulatory press releases

Cantargia is a biotechnology company specialising in dual-action antibody-based cancer treatments. CAN04, the company's patented antibody treatment, has a dual-action and fights cancer by activating the immune system and by blocking signals that lead to tumour growth. Treatment with CAN04 has the potential to become an important part of modern immunoncology.

Compared to similar treatments, Cantargias candidate CAN04 seems to offer a broader variety of treatment mechanisms towards the cancer".

SMALLCAP, Analys Anders Eriksson & Niklas Elmhammer, 2015-12-03

We estimate that the company has a good chance to reach their goal considering CAN04's unique target molecule and promising basic research".

REDEYE, Analysis 2016-10-07

How CAN04 attacks a cancer tumour

Watch the animated video

Press releases

* (R) = Regulatory press releases

Show more press releases  >>